The FDA approved Bayer’s asundexian (Sunharbo), the first drug in a new class aimed at reducing the risk of stroke in adults. The once-daily therapy targets secondary stroke prevention, adding a new option to the cardiovascular prevention toolkit as companies continue to pursue non–vitamin K antagonist approaches. For biotech and pharma teams, the approval matters not only for the specific product label but also for what it signals about regulatory readiness for next-generation anticoagulation mechanisms beyond standard regimens. Upcoming payer and guideline discussions will likely hinge on comparative effectiveness, patient selection, and bleeding-risk tradeoffs. Manufacturers and developers of competing antithrombotic strategies will watch for how FDA frames the benefit-risk profile and which endpoints anchored the decision.